Company Overview
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Revenue has grown at a 75.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $10.32M (+266.7% YoY); net profit $-129.77M.
- Trailing 12 Months Year-on-year growth — revenue -65.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 75.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 75.64% |
| 1 Year: | -65.80% |
Stock Price Performance
| 1 Year: | -80.52% |
| 6 Months: | -72.19% |
| 3 Months: | -65.31% |
| 1 Month: | -56.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)18.71 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 75.6% over 5 years.
CONS
- Trading 86.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 19 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TCRX TScan Therapeutics, Inc. PHARMA | 0.34 | -0.38 | $20.77M | 0.00% | -64.64% | -95.80% | 75.64% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 290.00K | 2.03M | 2.85M | 2.41M | 3.02M | 4.06M | 3.36M | 6.80M | 3.15M | 3.89M | 566.00K | 536.00K | 1.05M | - | 2.17M | 3.08M | 2.51M | 2.57M | 982.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.42M | 41.73M | 39.56M | 26.43M | 30.12M |
| Operating Income | -5.62M | -7.17M | -7.92M | -10.68M | -15.84M | -16.16M | -15.25M | -16.58M | -22.74M | -24.61M | -24.75M | -31.37M | -34.11M | -32.62M | - | -36.25M | -38.65M | -37.05M | -23.86M | -29.14M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.77M | -35.56M | -34.24M | -21.55M | -27.28M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 679.00K | 689.00K | 699.00K | 702.00K | 689.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.61M | -7.17M | -7.91M | -10.67M | -15.84M | -16.16M | -15.10M | -16.25M | -22.56M | -24.05M | -23.00M | -30.14M | -31.66M | -29.89M | - | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M |
| Diluted EPS | - | - | - | -7.69 | -0.80 | -0.67 | -0.63 | -0.67 | -0.93 | -0.51 | -0.24 | -0.32 | -0.28 | -0.25 | - | -0.26 | -0.28 | -0.28 | -0.18 | -0.22 |
| R&D Expense | 4.50M | 5.81M | 7.34M | 10.80M | 14.21M | 14.69M | 14.49M | 15.03M | 21.78M | 21.23M | 22.74M | 24.86M | 26.88M | 26.26M | - | 29.79M | 32.63M | 31.69M | - | 21.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.08M | - | 13.54M | 21.05M | 2.82M | 10.32M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 80.17M | 114.51M | 137.64M | 146.14M |
| Operating Income | -26.23M | - | -66.64M | -93.46M | -134.82M | -135.81M |
| EBITDA | - | - | -59.91M | -80.10M | -119.74M | -124.13M |
| Interest Expense | - | - | 1.18M | 3.76M | 3.65M | 2.77M |
| Pretax Income | - | - | -66.22M | -89.22M | -127.50M | -129.77M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -26.13M | - | -66.22M | -89.22M | -127.50M | -129.77M |
| Diluted EPS | - | - | -2.75 | -1.36 | -1.14 | -1.00 |
| R&D Expense | 20.58M | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 49.74M | - | 199.09M | 272.15M | 371.12M | 228.79M |
| Current Assets | - | - | - | 124.13M | 194.24M | 292.72M | 157.21M |
| Cash & Equivalents | - | 34.79M | - | 120.03M | 133.36M | 178.69M | 152.41M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 32.52M | - | 99.66M | 121.28M | 130.15M | 105.67M |
| Current Liabilities | - | 17.45M | - | 17.30M | 29.82M | 35.96M | 18.70M |
| Long Term Debt | - | - | - | 29.29M | 26.70M | 32.07M | 32.53M |
| Total Debt | - | - | - | 85.98M | 92.43M | 97.38M | 94.14M |
| Total Equity | -17.14M | -42.46M | - | 99.43M | 150.87M | 240.97M | 123.12M |
| Shares Outstanding | - | - | - | 24.23M | 47.83M | 56.59M | 56.90M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.02M | - | -66.50M | -61.36M | -110.82M | -135.32M |
| Investing Cash Flow | -4.24M | - | -4.22M | -60.76M | -52.61M | 109.37M |
| Financing Cash Flow | 288.00K | - | 29.36M | 135.44M | 208.76M | -336.00K |
| Capital Expenditure | -4.24M | - | -4.22M | -3.15M | -3.83M | -4.41M |
| Free Cash Flow | -7.26M | - | -70.73M | -64.50M | -114.65M | -139.73M |
| Net Change in Cash | - | - | -41.37M | 13.33M | 45.33M | -26.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -2,417.8% | - | -492.3% | -444.0% | -4,787.7% | -1,315.4% |
| Net Margin % | -2,408.0% | - | -489.3% | -423.9% | -4,527.7% | -1,256.8% |
| ROE % | 61.5% | - | -66.6% | -59.1% | -52.9% | -105.4% |
| ROCE % | -81.2% | - | -36.7% | -38.6% | -40.2% | -64.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lynx1 Capital Management Lp | 12.63% | 8.02M | $2.50M |
| 2 | BVF Inc. | 8.76% | 5.56M | $1.74M |
| 3 | Baker Bros. Advisors, LP | 4.39% | 2.78M | $868.58K |
| 4 | Vanguard Capital Management LLC | 3.40% | 2.16M | $673.34K |
| 5 | Two Sigma Investments, LP | 3.07% | 1.95M | $608.08K |
| 6 | Renaissance Technologies, LLC | 2.09% | 1.33M | $413.83K |
| 7 | Acadian Asset Management. LLC | 2.06% | 1.31M | $407.29K |
| 8 | Deer Management Co. LLC | 1.96% | 1.25M | $388.47K |
| 9 | Millennium Management Llc | 1.83% | 1.16M | $362.93K |
| 10 | Jacobs Levy Equity Management, Inc. | 1.65% | 1.05M | $327.43K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TCRX
All 13 tracked patients show full donor-cell replacement. TScan is cutting 75% of its workforce. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOWDg2TWRvZ0doY3J5QWIwWUpwYmVsM0s1ZXdlNWJIeGRBQ1J0OWdLekI3NE9UZWxqV3A1VnRWR09XUW1ucHhqZTRscHg3SzFvWkZHbTRoRjNRM1FfWHlnZ0ZmaE9aeGl4YzVaaWhCQkJmV0Vibi1pUFBRU3o4MlRMU21YaXltMDlhYWhkMl…
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOenNvV1hON3k0V0ZNajJuR24zUnY0ZFNLMnM2OUtESFNlTkQyaGxJaU1OcW9jaHJmaFAtMkpES05fTkNoRGZNRjV6Qk5TdjJCNFR3aVZGUmFlb2xGQTdfLUFCOXJUcVRuR2VoR3NwcmVZejJBZW1Bb01icjBSZVJJSXlKQ0ZkX21JRnNBXz…
TCRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9yTmkwUGFCYzlqanRXemx3QkJ1dkRWLS0wZHNvOWtyb0RUYUh1VFNmSF8xa0tTeWFjc2djWVUzajdJV3FQd1E?oc=5" target="_blank">TCRX</a> <font color="#6f6f6f">Finviz</font>…
TCRX Downgraded by Wedbush -- Price Target Lowered to $1.00 - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQODVVR3FWV2dzWlhaZGZZcml3cGhpaEx3WExERU4tOUdScFhKVVJaLVA0MXNFaEJFWUpUWEI3RVk4VHBVSldpWmxJMDMtQUpNeHllLWZvc0gyLUpPQ1NIS1pjRDVEdExQd1FiOWR4MzBoWEdiR2NUWkV5U3pDUzlWWFZwZXNpajk1YWZRMz…
TScan Therapeutics Reports $30.4 Million Q2 Net Loss - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQOWcybkljWGZYQ1ZlLWFJelNYNUJWSkZzckFkVWo1dk1PVkExWDdHM29oRHZCdE1aeEhoaUtkdmhoV2NuNzcycUlyUTBadXgySjFOWVpFR2xsdGN1VFhEdUtjSTBtekdsb2Q5WGh1cGczeG4zUXZBTzhRM3UzSnhDMklpeWExVEhzTlQ2VG…
TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - tradingview.com
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQMFVjSTUxbThENGNpQ0RzbGdVRFZmdDBRSVF4Q0Zjbks1MUt5elB3VVlaa2tfelJ5aXFsTG9nSTFlWFo5RlNHTXRkSFJXXzhRS0FJUDh4WE5vdWJDUEItUEkwdFpOdnRCRDhCNnVvNVFrVUcyS3pkOGNvUU5qZFNNaVJxbkllcWJ2WFphYj…
TCRX — Frequently Asked Questions
What is the current share price of TScan Therapeutics, Inc. (TCRX)?
As of 2026-09-19 21:16 PDT, TScan Therapeutics, Inc. (TCRX) trades at $0.34 on NasdaqGM. Its 52-week range is $0.34 to $2.52.
What is the market capitalisation of TCRX?
TScan Therapeutics, Inc. (TCRX) has a market capitalisation of $20.77M on NasdaqGM.
What is the P/E ratio of TCRX?
TCRX trades at a trailing price-to-earnings (P/E) ratio of -0.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.31.
What is the return on equity (ROE) of TCRX?
TCRX has a return on equity (ROE) of -95.80%. Its return on capital employed (ROCE) is -64.64%.
Is TCRX a good stock to buy?
This page provides a data-driven analysis of TScan Therapeutics, Inc. (TCRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.